Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NTRK”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04996121
What this trial is testing

XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 360
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213704
What this trial is testing

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor+30 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT02637687
What this trial is testing

Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 154
Not applicableNot Yet RecruitingNCT07599007
What this trial is testing

Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Early research (Phase 1)UnknownNCT05212987
What this trial is testing

Study of FCN-098 in Patients With Advanced Solid Tumor

Who this might be right for
Solid Tumor
Fochon Pharmaceuticals, Ltd. 43
Early research (Phase 1)Looking for participantsNCT06716138
What this trial is testing

Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd. 96
Early research (Phase 1)Study completedNCT02675491
What this trial is testing

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Who this might be right for
Advanced Solid Malignant Tumors
Daiichi Sankyo Co., Ltd. 15
Testing effectiveness (Phase 2)Ended earlyNCT02920996
What this trial is testing

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Who this might be right for
Carcinoma, Non-Small-Cell LungSolid Tumor
Dana-Farber Cancer Institute 12
Testing effectiveness (Phase 2)Looking for participantsNCT06239272
What this trial is testing

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Who this might be right for
Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+39 more
St. Jude Children's Research Hospital 139
Early research (Phase 1)Study completedNCT02219711
What this trial is testing

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Mirati Therapeutics Inc. 193
Early research (Phase 1)Study completedNCT02122913
What this trial is testing

Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 75
Not applicableNo Longer AvailableNCT03066661
What this trial is testing

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Who this might be right for
Cancers With NTRK, ROS1, or ALK Gene Fusions
Hoffmann-La Roche
Testing effectiveness (Phase 2)Looking for participantsNCT05783323
What this trial is testing

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid CancerPediatric CancerCancer+1 more
Children's Hospital of Philadelphia 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Early research (Phase 1)Ended earlyNCT03182257
What this trial is testing

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

Who this might be right for
Solid Tumor
Ono Pharmaceutical Co., Ltd. 1